|
LO-1
|
It explains the basic physiological functions of the metabolic and endocrine systems and the pathophysiological mechanisms of diseases. |
|
LO-2
|
It describes the etiology, risk factors, clinical findings, and basic diagnostic approaches of common metabolic and endocrine diseases. |
|
LO-3
|
It classifies and describes the drug groups used in the treatment of metabolic and endocrine diseases and their mechanisms of action. |
|
LO-4
|
This report evaluates the indications, adverse effects, contraindications, and significant drug interactions of medications used in the treatment of diabetes mellitus. |
|
LO-5
|
This section describes the basic pharmacotherapeutic approaches used in the treatment of thyroid, parathyroid, pituitary, and adrenal gland diseases. |
|
LO-6
|
It evaluates the role of medications used in the treatment of metabolic diseases such as obesity, metabolic syndrome, osteoporosis, and gout. |
|
LO-7
|
It evaluates the safety characteristics of drugs used in metabolic and endocrine diseases and the key parameters that should be monitored during treatment. |
|
LO-8
|
It evaluates rational and safe drug use in metabolic and endocrine diseases by considering the patient's individual characteristics, comorbidities, and other medications they are using. |